Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma

Figure 2

Durable responses after DAB/IL2 administration. On the left, baseline anterior/posterior views of FDG-PET imaging reveal multiple FDG-avid melanoma metastases in three clinical examples: A, 78 year-old female; B, 47 year-old male; and C, 62 year-old male. After DAB/IL2 administration, we observed a clinically significant and durable reduction in tumor burden, including hepatic metastases, pulmonary nodules, metatastic lymph nodes and subcutaneous nodules in all three patient examples.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us